The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

Meanwhile, Lilly gets in on the next-gen KRAS action.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.